FUJI YAKUHIN CO., LTD.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Private

Established: 1930-02-01

Employees: 10K

Market Cap: -

Website: http://www.fujiyakuhin.co.jp

Clinical Trials

Study of FYU-981 in Hyperuricemia With or Without Gout

Phase 2

Completed

Conditions: Hyperuricemia

Interventions: Drug: Placebo, (Oral daily dosing for 8 weeks)
Drug: FYU-981 Middle dose, (Oral daily dosing for 8 weeks)
Drug: FYU-981 High dose, (Oral daily dosing for 8 weeks)
Drug: FYU-981 Low dose, (Oral daily dosing for 8 weeks)

First Posted Date: 2015-01-26

Last Posted Date: 2015-01-26

Lead Sponsor: Fuji Yakuhin Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT02344862

Locations: 🇯🇵
Japan, Tokyo, Japan

Clinical Pharmacology of FYU-981 (Elder Subjects)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: FYU-981, (Oral single dosing)

First Posted Date: 2015-01-26

Last Posted Date: 2015-01-26

Lead Sponsor: Fuji Yakuhin Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT02344875

Locations: 🇯🇵
Japan, Tokyo, Japan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy